Answer
Orkambi may decrease montelukast exposure and thereby reduce its efficacy; no montelukast dose adjustment is recommended, but appropriate clinical monitoring should be employed.
Sources for this answer
- Orkambi 200 mg/125 mg film coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 19Document updated
Sources checked